Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, discusses the significance TP53 mutation status on chronic lymphocytic leukemia (CLL), as evaluated by a multicenter ERIC study comparing methods used for identifying the presence of TP53 mutations in CLL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).